1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H2 2020, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.
Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 18, 12, 4, 70, 19 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 3 molecules, respectively.
Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionGlaucoma - Overview
Glaucoma - Therapeutics Development
Glaucoma - Therapeutics Assessment
Glaucoma - Companies Involved in Therapeutics Development
Glaucoma - Drug Profiles
Glaucoma - Dormant Projects
Glaucoma - Discontinued Products
Glaucoma - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Glaucoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Glaucoma - Pipeline by AbbVie Inc, H2 2020
- Glaucoma - Pipeline by AC Immune SA, H2 2020
- Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
- Glaucoma - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
- Glaucoma - Pipeline by Allergan Ltd, H2 2020
- Glaucoma - Pipeline by Amgen Inc, H2 2020
- Glaucoma - Pipeline by Annexon Inc, H2 2020
- Glaucoma - Pipeline by Annovis Bio Inc, H2 2020
- Glaucoma - Pipeline by Asha Vision LLC, H2 2020
- Glaucoma - Pipeline by Betaliq Inc, H2 2020
- Glaucoma - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
- Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2020
- Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2020
- Glaucoma - Dormant Projects, H2 2020
- Glaucoma - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Glaucoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- AC Immune SA
- Aerie Pharmaceuticals Inc
- Aerpio Pharmaceuticals Inc
- Allergan Ltd
- Amgen Inc
- Annexon Inc
- Annovis Bio Inc
- Asha Vision LLC
- Betaliq Inc
- Better Life Pharmaceuticals Inc
- Bial - Portela & Ca SA
- BioAxone BioSciences Inc
- Biozeus Pharmaceutical SA
- Califia Bio Inc
- Calpain Therapeutics Pty Ltd
- Cellix Bio Pvt Ltd
- Certa Therapeutics Pty Ltd
- Chong Kun Dang Pharmaceutical Corp
- D. Western Therapeutics Institute Inc
- Deha Pharmaceutical LLC
- Dhp Korea Ltd
- Disarm Therapeutics Inc
- Dompe Farmaceutici SpA
- Emerald Bioscience Inc
- Emerald Organic Products Inc
- Envisia Therapeutics Inc
- Evotec SE
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- Fortress Biotech Inc
- Future Medicine Co Ltd
- Galimedix Therapeutics Ltd
- Gene Signal International SA
- Glaukos Corp
- Graybug Vision Inc
- Guangzhou Cellprotek Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Gurus BioPharm
- Handok Inc
- HitGen Inc
- HK inno.N Corp
- ID Pharma Co Ltd
- Il Dong Pharmaceutical Co Ltd
- InMed Pharmaceuticals Inc
- Inspyr Therapeutics Inc
- Isarna Therapeutics GmbH
- Kedalion Therapeutics Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- Kyoto Drug Discovery & Development Co Ltd
- Laboratoires Thea SA
- Laboratorios Salvat SA
- Laboratorios Sophia SA de CV
- LayerBio Inc
- Lee's Pharmaceutical Holdings Ltd
- Luminus Biosciences Inc
- Matrix Biomed Inc
- MimeTech Srl
- MyX Therapeutics Inc
- Nanoscope Therapeutics Inc
- NeurAegis Inc
- Neurim Pharmaceuticals Ltd
- Neurizon Pharma GBR
- Neuroptika Inc
- NeuroScientific Biopharmaceuticals Ltd
- NicOx SA
- NoNO Inc
- Novaliq GmbH
- Novartis AG
- Noveome Biotherapeutics Inc
- Novoron Bioscience Inc
- OccuRx Pty Ltd
- Ocular Therapeutix Inc
- Oculo Therapy LLC
- Ocuphire Pharma Inc
- Oncolys BioPharma Inc
- ONL Therapeutics Inc
- Palo BioFarma SL
- pH Pharma Co Ltd
- Pinotbio Inc
- Profarma
- Q BioMed Inc
- Qlaris Bio Inc
- Quark Pharmaceuticals Inc
- Qurgen Inc
- Radikal Therapeutics Inc
- ReNetX Bio
- Reven Pharmaceuticals Inc
- Ripple therapeutics Corp
- Santen Pharmaceutical Co Ltd
- Stuart Therapeutics Inc
- Sun Pharma Advanced Research Company Ltd
- Sustained Nano Systems LLC
- Sylentis SAU
- TaeJoon Pharmaceuticals Co Ltd
- TearClear Corp
- Teraclon IDF SL
- TikoMed AB
- Toa Eiyo Ltd
- Topadur Pharma AG
- ViSci Ltd
- Whitecap Biosciences LLC
